Enanta Pharmaceuticals Inc (NASDAQ: ENTA) on Friday, soared 7.17% from the previous trading day, before settling in for the closing price of $5.86. Within the past 52 weeks, ENTA’s price has moved between $5.70 and $17.80.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -19.00%. The company achieved an average annual earnings per share of 14.44%. With a float of $19.73 million, this company’s outstanding shares have now reached $21.19 million.
Let’s determine the extent of company efficiency that accounts for 131 employees. In terms of profitability, gross margin is 98.13%, operating margin of -179.92%, and the pretax margin is -174.15%.
Enanta Pharmaceuticals Inc (ENTA) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Enanta Pharmaceuticals Inc is 6.90%, while institutional ownership is 100.34%. The most recent insider transaction that took place on Dec 06 ’24, was worth 18,401. In this transaction Chief Product Strategy Officer of this company sold 2,283 shares at a rate of $8.06, taking the stock ownership to the 29,305 shares. Before that another transaction happened on Dec 06 ’24, when Company’s Chief Business Officer sold 2,283 for $8.06, making the entire transaction worth $18,401. This insider now owns 36,047 shares in total.
Enanta Pharmaceuticals Inc (ENTA) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 14.44% per share during the next fiscal year.
Enanta Pharmaceuticals Inc (NASDAQ: ENTA) Trading Performance Indicators
Enanta Pharmaceuticals Inc (ENTA) is currently performing well based on its current performance indicators. A quick ratio of 5.21 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.11.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.49, a number that is poised to hit -1.27 in the next quarter and is forecasted to reach -3.89 in one year’s time.
Technical Analysis of Enanta Pharmaceuticals Inc (ENTA)
Looking closely at Enanta Pharmaceuticals Inc (NASDAQ: ENTA), its last 5-days average volume was 0.56 million, which is a jump from its year-to-date volume of 0.22 million. As of the previous 9 days, the stock’s Stochastic %D was 7.63%. Additionally, its Average True Range was 0.65.
During the past 100 days, Enanta Pharmaceuticals Inc’s (ENTA) raw stochastic average was set at 6.16%, which indicates a significant decrease from 14.91% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 118.53% in the past 14 days, which was higher than the 64.98% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $9.78, while its 200-day Moving Average is $12.44. However, in the short run, Enanta Pharmaceuticals Inc’s stock first resistance to watch stands at $6.49. Second resistance stands at $6.69. The third major resistance level sits at $7.08. If the price goes on to break the first support level at $5.90, it is likely to go to the next support level at $5.51. Should the price break the second support level, the third support level stands at $5.31.
Enanta Pharmaceuticals Inc (NASDAQ: ENTA) Key Stats
Market capitalization of the company is 142.64 million based on 21,194K outstanding shares. Right now, sales total 67,640 K and income totals -116,050 K. The company made 14,610 K in profit during its latest quarter, and -28,820 K in sales during its previous quarter.
